WTR Healthcare Happenings
WTR Healthcare Happenings is a weekly conversation with healthcare executives, medical experts, and investors on recent clinical data or industry-driving events in healthcare.
Episodes
58 episodes
Pulsenmore (PLSM): Safe and Sound: Pulsenmore Brings Prenatal Ultrasound Home
In this episode of the WTR Healthcare Happenings Podcast, host Tim Gerdeman and WTR equity research analyst James Kisner talk with Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore Ltd. (Nasdaq and Tel Aviv: PLSM). Pulsenmore has built the...
Jupiter Neurosciences (JUNS): Jotrol’s Bioavailability Breakthrough and the Key Parkinson’s Phase 2A Readout
In this episode, Christer Rosen, Founder and CEO of Jupiter Neurosciences (Nasdaq: JUNS), and President & COO Alison Silva join Water Tower Research’s Tim Gerdeman and Healthcare Analyst Robert Sassoon to discuss Jotrol, the company’s propr...
NurExone Biologic (NRX): The Inhibitor of the Inhibitor: How Nurexone's ExoPTEN Is Designed to Restart Nerve Regeneration
In this episode of Healthcare Happenings, Robert Sassoon, WTR healthcare equity analyst, joins host Tim Gerdeman to discuss his initiation of coverage on NurExone Biologic (TSXV: NRX / OTCQB: NRXBF), a preclinical biopharma company advancing a ...
PharmAla Biotech (MDMA): Two Transactions, One Strategy: Unlocking Pipeline Value Through Structured Partnerships
In this episode of Healthcare Happenings, Nick Kadysh, Founding CEO and President of PharmAla Biotech (CSE: MDMA / OTCQB: MDXXF), joins host Tim Gerdeman and WTR healthcare analyst Robert Sassoon to discuss two recently announced transactions. ...
Solvonis Therapeutics (SVNS): CSO Professor David Nutt on Solvonis' Approach to Resetting the Addicted Brain
In this special episode of the WTR Healthcare Happenings podcast, the second in a two-part series, Professor David Nutt, Chief Science Officer of Solvonis Therapeutics (LSE: SVNS), talks to host Tim Gerdeman and WTR analyst Robert Sassoon about...
Solvonis Therapeutics (SVNS): Rewriting the Standard of Care for Severe Alcohol Use Disorder
In this special episode of Healthcare Happenings, the first in a two‑part series, Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), joins host Tim Gerdeman and WTR analyst Robert Sassoon to discuss the company’s strategy in a...
PetVivo Holdings (PETV): The Trifecta: Regenerative Science, AI-Enabled Vet Care, and Human Translation
In this episode of Healthcare Happenings, John Lai, CEO of PetVivo Holdings (PETV), joins host Tim Gerdeman and WTR analyst Robert Sassoon to discuss the company's regenerative medicine platform for companion animals. The conversation covers Pe...
SBC Medical (SBC): Scaling Aesthetics, Longevity, and Global Growth
In this episode of the WTR Healthcare Happenings podcast, Stephen Rodgers, Head of Global Planning and Strategy at SBC Medical Group Holdings (NASDAQ: SBC), joins WTR’s Tim Gerdeman and Robert Sassoon. Rodgers discusses how SBC’s...
ExoZymes (EXOZ): Unlocking Hard-to-Scale Molecules with AI-Driven, Cell-Free Biomanufacturing
ExoZymes (NASDAQ: EXOZ) CEO Michael Heltzen joins Tim Gerdeman and Robert Sassoon in this episode of the WTR Healthcare Happenings podcast to discuss the company’s AI-driven, cell-free biomanufacturing platform and how it aims to overcome longs...
Hidden Gems - Unlocking Value in Biotech's Most Overlooked Stocks
On the latest WTR Healthcare Happenings podcast, we were joined by David Sans, PhD, a healthcare investment banker, and our host, Tim Gerdeman, WTR’s Vice-Chair, Co-Founder, and Chief Marketing Officer. Over the past two ye...
Vivos Therapeutics (VVOS): 2025 Results and Path to Cash Flow Breakeven by End-2026
On this episode, Vivos Therapeutics (NASDAQ: VVOS) CEO Kirk Huntsman joins WTR’s Tim Gerdeman and Robert Sassoon on Healthcare Happenings to discuss the company’s 2025 results and the momentum behind its shift from a dentist‑led model ...
Trump's Psychedelic Medicine Executive Order: What It Means for Patients and Investors
Water Tower Research's healthcare equity analyst Robert Sassoon breaks down President Trump's executive order on therapeutic psychedelics, examining the five key mechanisms it puts in place — from accelerated FDA review vouchers and right-to-tr...
WTR Insights Conference Preview: Nurexone's Nerve Regeneration & Anixa's Cancer Immunotherapy in Focus
In this special preview episode of WTR Healthcare Happenings, Robert Sassoon spotlights two biotechs presenting on Day 1 of the WTR Insights Conference (April 14–15). Nurexone Biologic (TSX-V: NRX | OTCQB: NRXBF) is pioneer...
Circular Genomics: Cracking the Brain Code with Circular RNA
In this episode of the WTR Healthcare Happenings podcast, Water Tower Research’s Shawn Severson and Robert Sassoon are joined by Dr. Paul Sargeant, President and CEO of Circular Genomics, a privately held molecular diagnostics company developin...
Unmasking the Treatment Landscape for Obstructive Sleep Apnea (OSA)
Robert Sassoon, WTR Senior Healthcare Analyst, joins Tim Gerdeman to discuss obstructive sleep apnea (OSA) and the rapidly evolving treatment landscape for this widespread yet often undiagnosed and potentially fatal condition. The conversation ...
Psychedelics at a Turning Point: The Trials That Could Change Mental Health Treatment
Robert Sassoon, WTR Senior Healthcare Analyst, joins Shawn Severson, CEO of WTR, to break down the latest clinical readouts in advanced psychedelics — including Compass Pathways’ Phase III progress in treatment-resistant depression, new anxiety...
Anixa Biosciences (ANIX): CEO Dr. Amit Kumar on Why 2026 Is Poised to Be a Defining Year
In this episode of the WTR Healthcare Happenings, we welcome back Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (NASDAQ: ANIX) who explains why 2026 is shaping up to be a pivotal year for the company. Building on the momen...
Omniscient Neurotechnology: Scaling up Clinical Connectomics SaaS Strategy and Neurotech Vision
In this episode of the WTR Healthcare Happenings, Adam Fraser, COO of Omniscient Neurotechnology—a privately held, Australian‑based but U.S.-focused company pioneering AI‑driven brain mapping—joins Water Tower Research Co‑Founder Tim Gerdeman a...
Decoy Therapeutics (DCOY): CEO Rick Pierce on the Company’s Groundbreaking Approach to Drug Development in the AI/ML Era
In this episode of the WTR Healthcare Happenings podcast, Rick Pierce, CEO of Decoy Therapeutics (NASDAQ: DCOY), joins Tim Gerdeman, Vice Chair, Co‑Founder, and CMO of Water Tower Research, and Robert Sassoon, WTR’s Healthcare Research Analyst....
NurExone Biologic (OTCQB: NRXBF / TSXV: NRX): CEO Dr. Lior Shaltiel on How the Company Stands Out as an Early‑Clinical‑Stage Biotech
In this episode of WTR Healthcare Happenings, Dr. Lior Shaltiel, CEO of NurExone Biologic (OTCQB: NRXBF / TSXV: NRX), joins Tim Gerdeman and Robert Sassoon to discuss how the company is positioning itself as a...
Taking Aim at Norovirus; Cocrystal Pharma's (COCP) Clinical Antiviral Opportunity
In this episode of the WTR Healthcare Happenings Podcast, Tim Gerdeman and Robert Sassoon speak with Jim Martin, Co‑CEO and CFO of Cocrystal Pharma (NASDAQ: COCP). Martin explains the company’s Nobel Laureate‑developed drug discovery p...
How Entropy Neurodynamics (ASX: ENP) Is Shaping Psychedelic‑Assisted Therapy: Psilocin Programs, Binge Eating Disorder, and EEG Biomarker
In this episode of the WTR Healthcare Happenings Podcast, host Tim Gerdeman and healthcare analyst Robert Sassoon are joined by Dr. Jim Gilligan, President and Chief Science Officer of Entropy Neurodynamics (ASX: ENP), formerly Tryptamine Thera...
Anixa' (ANIX) T-Cell Innovations Demonstrate Early Breakthrough Potential in Solid Tumors
In this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman sits down with WTR Healthcare analyst Robert Sassoon to discuss his Initiation of Coverage Report on Anixa Biosciences. Their conversation explore...
The lure of the NASDAQ for Biotechs
In this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman and WTR Healthcare analyst Robert Sassoon break down why more than 90% of biotech companies listed on a U.S. exchange choose NASDAQ over the NYSE.
Redefining Cancer Treatment: Calidi Biotherapeutics’ Approach to Enable Systemic Oncolytic Virotherapy for Metastatic Disease
In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Eric Poma PhD, CEO of Calidi Biotherapeutics Inc (NYSE American: CLDI). The discussion focuses on how Calidi is sol...